Equity Overview
Price & Market Data
Price: $5.41
Daily Change: +$0.05 / 0.92%
Daily Range: $5.10 - $5.43
Market Cap: $343,552,672
Daily Volume: 222,989
Performance Metrics
1 Week: -1.81%
1 Month: -1.28%
3 Months: %
6 Months: -15.07%
1 Year: -29.10%
YTD: -0.73%
Company Details
Employees: 106
Sector: Health technology
Industry: Biotechnology
Country:
Details
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.